The P4 Precision Medicine Accelerator, dedicated to supporting the UK’s leading medtech startups, has announced the names of the ten companies selected to participate in its 2023 cohort.

Over the next six months, these startups will benefit from access to academic and tech industry expertise, tailored mentorship, support navigating regulatory approvals, and investor introductions as they develop their technologies and bring them to market.

Selected from more than 60 applications, these are the ten companies that are set to join P4’s 2023 cohort:

Alcyomics are developing in vitro human skin models for use in drug development and toxicity testing with the goal of accelerating the testing process for new drugs and better predicting clinical outcomes. This is aimed at reducing drug development costs, as well as reliance on animal testing, and improving speed to market for new drug candidates. 

Bioleap is developing a systems medicine platform that leverages proprietary hybrid biophysical / AI computational models of complex disease systems to better predict the efficacy of complex immunotherapies, whilst providing additional insights into possible co-target or combination therapies and best next experiments for maximal information gain. Their initial focus is on modelling the tumour microenvironment and associated immunotherapies such as on Oncolytic viruses, Car-T therapies, checkpoint inhibitors and cancer vaccines.

Echopoint Medical are developing non-invasive devices for precision interventions with optical sensing. With the iKor platform, they are working to address a challenge faced by interventional cardiologists who diagnose and treat patients suffering from certain types of chest pain. The iKor platform enables therapy guidance with just one device that fits into preexisting cardiology workflows. 

Ru medical are focused on developing innovative solutions to improve patient outcomes. Their first product is Coolzen, a wearable designed to detect the start of a hot flash for women going through menopause and automatically trigger neural pathways to diminish its intensity.

Myndspan has developed tools that use artificial intelligence and machine learning to analyse brainwave data. This has potential for a variety of applications, including improving mental health diagnosis and developing new treatments for neurological disorders.

ZiO Health has developed proprietary biosensor technology that powers their AI-driven, hand-held point-of-care device for therapeutic drug monitoring (TDM) and precision dosing to improve patient drug treatment outcomes.

NE Scientific is a biotech company focused on developing novel surgical guidance tools for application in the oncological space. The company provides real-time simulation technologies that are used to support physicians in better targeting tissues during a variety of minimally invasive procedures. This technology can significantly improve the chances that a tumour is completely eradicated in a single session, reducing the probability of recurrence, and significantly reducing time demands on the physician.

NX10 predicts and manages brain health, harnessing brain performance data to allow patients to lead longer and healthier lives. By identifying early signs of cognitive decline and working to detect early symptoms of dementia, they enable patients to take control of their life planning and make the most of the most precious commodity – time.

Qured is a preventative healthcare platform which empowers employees to take control of their health through personalised screening programmes, from vital organ function to common cancers and fertility/menopause. Qured’s technology allows testing and clinical support to be delivered to employees at home and provides businesses with workforce health analytics. Qured has partnered with the likes of American Express, British Airways, and Transport for London among many others.

HearingPower has developed the Tinnibot app, a companion for tinnitus relief to support individuals suffering from tinnitus. Using advanced algorithms and machine learning, the goal is to provide personalised guidance that empowers the user to adapt their reaction to the tinnitus so it becomes less noticeable. Tinnibot incorporates cognitive-behavioural exercises, meditation, journaling, and soundscapes to ensure optimal effectiveness.

“I’m excited to welcome these fantastic companies to the P4 family,” said Nathan McNally, co-founder of the accelerator. “The entire P4 team look forward to working with them. These companies were selected on their ability to tackle patient needs in the precision medicine space or deliver significant insights to move precision medicine forwards. Each of these companies has tremendous potential to make an impact in the healthcare sector and transform the lives of patients for the better, and I’m already looking forward to the milestones they achieve through the programme.”

Since 2019, the P4 Precision Medicine Accelerator Programme has supported more than 170 companies and projects which have gone on to raise over £200 million in private investment and £30 million in grant funding. The accelerator has quickly established itself for its ability to attract some of the most promising medtech startups in the UK. The ‘four Ps’ are predictive, preventative, participatory, and precision.